Malaria Clinical Trial
— (PCMT)Official title:
Responding to Efficacy Decay Analysis of Artemisinin Based Combination Therapy (ACTs) in Rural Tanzania: Intervening on Provider Compliance and Patient Adherence to Correct Malaria Treatment
INDEPTH Network Effectiveness and Safety Studies in Africa (INESS) have demonstrated a
substantial efficacy decay of Artemisinin based combination therapy (ACT) in Tanzania in
2012 (from efficacy of 98% to effectiveness of 18%). Hence system readiness for control and
elimination strategies is severely compromised. Sub-optimal health workers' performance in
treating malaria cases was a major contributor to the decay, effecting both treatment and
patient adherence. If these quantified system failures remain unchecked it will pose major
barrier in achieving malaria control and elimination goals. There is growing evidence that
mobile phone text message reminders can improve health workers' compliance and patients'
adherence to malaria treatment guidelines. Tanzania has recently harnessed all public sector
health worker phones into Short Message System (SMS) platform. The investigators intend to
exploit this opportunity in a randomized trial of messages to substantially reduce the decay
documented by the INESS platform.
The null hypothesis: Sending automated text message reminders to health workers on malaria
diagnosis and treatment recommendations, will not have any effects in the quality of malaria
case management.
Status | Recruiting |
Enrollment | 712 |
Est. completion date | December 2015 |
Est. primary completion date | December 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: Dispensaries and health centers; public and private; operating in Rufiji district that provided outpatient services will be eligible for the study. In the intervention arm facility, all health workers who see and take care of patients at the outpatient department (OPD) will be registered to receive automated SMS as the intervention in this study. During the evaluation phase, all patients attending the surveyed facilities for initial illness consultation will be eligible for inclusion in the study. Assessment of adherence will be performed to malaria patients (who tested positive) and received ACT for treatment. Exclusion Criteria: Due to logistical difficulties, health facilities within the Delta region will be excluded in this study. As well, two hospitals in the district will be excluded in the study since they mostly receive referral patients. Also, hospitals have specialized clinic sections with highly trained staff and their nurses or clinicians may be rotating in different departments, hence there may not be health provider's whose primary duties are on OPD patients alone. In addition, health workers in eligible facilities who do not own a mobile phone will be excluded to receive "SMS" reminders. During evaluation, all severe cases and hospitalized patients will not be included in the surveys. Assessment of adherence study will exclude non residents of the study area. |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research
Country | Name | City | State |
---|---|---|---|
Tanzania | Ifakara Health Institute | Rufiji | Pwani |
Lead Sponsor | Collaborator |
---|---|
Ifakara Health Institute | KEMRI-Wellcome Trust Collaborative Research Program, Swiss Tropical & Public Health Institute |
Tanzania,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Provider Compliance | Proportion of patients presenting to health provider for initial illness consultation with fever (documented fever or history of fever within 48 hours); who are tested for malaria and prescribed ACT for test positive results or not prescribed any antimalarial for test negative results. | 10 months | No |
Secondary | Number of fever patients who received diagnostic test | 1) Proportion of fever patients receiving a diagnostic test to rule out/in malaria as per national guidelines. | 10 months | No |
Secondary | Number of confirmed malaria patients treated with recommended antimalaria | Proportion of malaria patients (fever with a positive test routine and gold standard) treated according to malaria treatment guidelines. | 10months | No |
Secondary | Number of malaria patients who received correct dose of ACT | Proportion of patients who receive a correct dose of ACT based on age and/or body weight for malaria treatment | 10 months | No |
Secondary | Number of patients with a negative malaria test who did not receive antimalaria | Proportion of negative tested patients who did not receive antimalarials | 10 months | No |
Secondary | Number of afebrile patients who are tested for malaria | Proportion of non-febrile (no fever or no history of fever within 48 hours) patients who are tested for malaria | 10 months | No |
Secondary | Number of patients who received counselling messages | Proportion of patients who received recommended counseling messages | 10 months | No |
Secondary | Number of patients who completed antimalaria doses as instructed | Proportion of complete and incomplete adherent patients, as prescribed by health worker. | 10 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
Completed |
NCT02605720 -
Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns
|
Phase 3 |